February 27, 2007 – Threshold lost almost 60% after reporting glufosfamide did not meet its endpoint in a Phase III trial; Par Pharma returned the rights for diarrhea drug Difimicin to Optimer; Teva partnered with Vaccinex to develop a targeted therapy for MS; Cytogen began a Phase I trial of CYT-500, its radiolabeled prostate cancer drug; Celera published data that identifies genetic markers of Alzheimer’s disease with genes that regulate glucose; Kosan and Roche selected a second-generation epothilone cancer drug; and Tongjitang Chinese Medicines Company filed its initial submission for an American IPO. The Centient Biotech 200™ lost 3.16% of its value, falling 128 points to end at 3927. More details...
